Evidence map›Paper›PMID 28472040›Full record

ArticlePloS one2017

Ultra-deep sequencing reveals high prevalence and broad structural diversity of hepatitis B surface antigen mutations in a global population.

Mikael Gencay, Kirsten Hübner, Peter Gohl, Anja Seffner, Michael Weizenegger, Dionysios Neofytos, Richard Batrla, Andreas Woeste, Hyon-Suk Kim, Gaston Westergaard and 14 more

Abstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Mikael GencayRoche Diagnostics International Ltd, Rotkreuz, Switzerland.
Kirsten HübnerBioscientia Institute for Medical Diagnostics, Ingelheim, Germany.
Peter GohlBioscientia Institute for Medical Diagnostics, Ingelheim, Germany.
Anja SeffnerDepartment of Molecular Genetics and Microbiology, MVZ Labor Dr. Limbach & Kollegen GbR, Heidelberg, Germany.
Michael WeizeneggerDepartment of Molecular Genetics and Microbiology, MVZ Labor Dr. Limbach & Kollegen GbR, Heidelberg, Germany.
Dionysios NeofytosRoche Diagnostics International Ltd, Rotkreuz, Switzerland.
Richard BatrlaRoche Diagnostics International Ltd, Rotkreuz, Switzerland.
Andreas WoesteRoche Diagnostics GmbH, Penzberg, Germany.
Hyon-Suk KimDepartment of Laboratory Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea.
Gaston WestergaardRoche Diagnostics International Ltd, Rotkreuz, Switzerland.
Christine ReinschRoche Diagnostics GmbH, Mannheim, Germany.
Eva BrillBioscientia Institute for Medical Diagnostics, Ingelheim, Germany.
Pham Thi Thu ThuyHepatology Department, Medic Medical Center, Ho Chi Minh City, Vietnam.
Bui Huu HoangGastroenterology Department, Ho Chi Minh City University Medical Center, Ho Chi Minh City, Vietnam.
Mark SonderupDivision of Hepatology and Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa.
C Wendy SpearmanDivision of Hepatology and Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa.
Stephan PabingerAIT Austrian Institute of Technology, Health and Environment Department, Molecular Diagnostics, Vienna, Austria.
Jérémie GautierCerba Spécimen Services, Saint-Ouen l'Aumône, France.
Giuseppina BrancaccioInfectious Diseases and Viral Hepatitis Unit, Second University of Naples, Naples, Italy.
Massimo FasanoInfectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy.
Teresa SantantonioInfectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy.
Giovanni B GaetaInfectious Diseases and Viral Hepatitis Unit, Second University of Naples, Naples, Italy.
Markus NauckBioscientia Institute for Medical Diagnostics, Ingelheim, Germany.
Wolfgang E KaminskiBioscientia Institute for Medical Diagnostics, Ingelheim, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The diversity of the hepatitis B surface antigen (HBsAg) has a significant impact on the performance of diagnostic screening tests and the clinical outcome of hepatitis B infection. Neutralizing or diagnostic antibodies against the HBsAg are directed towards its highly conserved major hydrophilic region (MHR), in particular towards its "a" determinant subdomain. Here, we explored, on a global scale, the genetic diversity of the HBsAg MHR in a large, multi-ethnic cohort of randomly selected subjects with HBV infection from four continents. A total of 1553 HBsAg positive blood samples of subjects originating from 20 different countries across Africa, America, Asia and central Europe were characterized for amino acid variation in the MHR. Using highly sensitive ultra-deep sequencing, we found 72.8% of the successfully sequenced subjects (n = 1391) demonstrated amino acid sequence variation in the HBsAg MHR. This indicates that the global variation frequency in the HBsAg MHR is threefold higher than previously reported. The majority of the amino acid mutations were found in the HBV genotypes B (28.9%) and C (25.4%). Collectively, we identified 345 distinct amino acid mutations in the MHR. Among these, we report 62 previously unknown mutations, which extends the worldwide pool of currently known HBsAg MHR mutations by 22%. Importantly, topological analysis identified the "a" determinant upstream flanking region as the structurally most diverse subdomain of the HBsAg MHR. The highest prevalence of "a" determinant region mutations was observed in subjects from Asia, followed by the African, American and European cohorts, respectively. Finally, we found that more than half (59.3%) of all HBV subjects investigated carried multiple MHR mutations. Together, this worldwide ultra-deep sequencing based genotyping study reveals that the global prevalence and structural complexity of variation in the hepatitis B surface antigen have, to date, been significantly underappreciated.

Indexed as

Global HealthHigh-Throughput Nucleotide SequencingMutationAmino Acid SubstitutionGenotypeHepatitis B Surface AntigensHepatitis B virusHumansHydrophobic and Hydrophilic InteractionsHepatitis B Surface Antigens

Identifiers

PMID28472040
PMCPMC5417417

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.